{"id":99,"date":"2024-06-26T13:52:04","date_gmt":"2024-06-26T13:52:04","guid":{"rendered":"https:\/\/www.merckvaccines.com\/vaxneuvance\/?page_id=99"},"modified":"2026-02-23T09:07:43","modified_gmt":"2026-02-23T09:07:43","slug":"immunogenicity","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/vaxneuvance\/immunogenicity\/","title":{"rendered":"Immunogenicity"},"content":{"rendered":"\n\n
<\/div>\"\"<\/picture>

Choose the robust and early protection of VAXNEUVANCE<\/strong><\/strong><\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n\n
<\/div>\n\n\n\n\n
\n
<\/div>\n\n\n\n\n

VAXNEUVANCE delivers superior immune responses at 7 months for 3 key disease-causing serotypes1,a-c<\/sup><\/strong><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n

Superior immune responses for critical disease-causing Serotypes 3, 22F, and 33F<\/strong>1,b-d<\/sup><\/p>\n<\/div>\n\n\n\n

\n\n
\"Image\"Image<\/figure><\/div><\/div>\n<\/div>\n\n\n\n
\n

Comparable immune responses for 12 shared serotypes<\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

VAXNEUVANCE was studied vs PCV13.<\/strong><\/h3><\/div>\n\n\n\n

Randomized controlled trials assessing the clinical efficacy of VAXNEUVANCE compared to PCV13 have not been conducted.\u2028<\/p>\n\n\n\n

No randomized controlled clinical trials have been conducted between PCV20 and VAXNEUVANCE in pediatric patients.<\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n

VAXNEUVANCE provides superior immune responses postdose 3 and postdose 4 for Serotype 3a-d<\/sup><\/span><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/div>\n\n\n\n

Postdose 3 IgG response rates for Serotype 3 vs PCV13b<\/sup><\/strong><\/p>\n\n\n\n

<\/div>\n<\/div>\n\n\n\n
\n
\"Serotype\"Serotype<\/figure><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

Serotype 3 Postdose 3c<\/sup><\/strong><\/h3><\/div>\n\n\n\n
\n
\n
\n
\n
\"70%\"\"70%\"<\/figure><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n

higher immunogenicity vs PCV13<\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n

IgG GMC Ratio vs PCV13, 1.70 (95% CI: 1.54, 1.86)<\/span><\/p><\/div><\/div>\n\n\n\n

<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n